drugset / Trial / NCT03702738

Adjunctive NAC in Adult Patients With Pulmonary Tuberculosis

NCT03702738

RandomizedParallel-groupOpen-labelTreatment

Summary

To determine if adjunctive N-acetylcysteine 1200 mg twice a day (BID) accelerates sputum culture conversion and normalization of cellular glutathione in tuberculosis (TB), and to assess its potential effects on lung and immune function

Timeline

Start
2019-03-01
Primary completion
2021-12-31
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule 1200 mg Oral